RIBOCICLIB AND ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER-2) BREAST CANCER: THE MONALEESA CLINICAL TRIALS PROGRAM-MedSci.cn

RIBOCICLIB AND ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER-2) BREAST CANCER: THE MONALEESA CLINICAL TRIALS PROGRAM

Campone, M; Tripathy, D; Chia, S; Diaz-Padilla, I; Lorenc, KR; Miller, M; Germa, C; Conte, P

BREAST, 2017; 36 ( ): S50

科室
- - 订阅+
  - 更多科室
工具
服务